The Impact of Radiotherapy on Oligometastatic Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem nowotwór piersi, prostaty, płuc lub jelit
- •Wiek 18 lat lub więcej
- •Do pięciu przerzutów w kościach, płucach, węzłach chłonnych, wątrobie lub mózgu
- •Dobry stan ogólny (skala ECOG 0 lub 1)
✗ Disqualifies
- •Rak skóry (inny niż czerniak)
- •Wcześniejsza radioterapia w tym samym miejscu
- •Choroby autoimmunologiczne tkanki łącznej
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- November 18, 2024
- Sex
- No restrictions
Therapies / drugs in trial
Locations (21)
Complejo Hospitalario Universitario Albacete
Albacete, Spain
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Institut Català d'Oncologia
Barcelona, Spain
Hospital Universitario Virgen de las Nieves
Granada, Spain
Hospital Universitari Arnau de Vilanova
Lleida, Spain
Hospital de La Luz
Madrid, Spain
Hospital Ruber Internacional
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
Hospital Universitario Quirónsalud
Madrid, Spain
Hospital Universitario Rey Juan Carlos
Madrid, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Universitari Sant Joan de Reus
Reus, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital General Univesitario de Valencia
Valencia, Spain
Hospital Universitari Miguel Servet
Zaragoza, Spain
Hospital del Mar
Barcelona, Spain
Hospital Provincial de Castellón
Castellon, Spain
Institut Català d'Oncologia
Girona, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital de Terrassa
Terrassa, Spain
Trial contact
Jorge Joven, Prof.
Meritxell Arenas, PhD.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.